HIGH-POTENCY ANTIHAEMOPHILIC FACTOR CONCENTRATE PREPARED FROM CRYOGLOBULIN PRECIPITATE.
about
Progress and challenges in the development of a cell-based therapy for hemophilia AAcute intravascular haemolysis associated with cephalexin therapyThe evolution of comprehensive haemophilia care in the United States: perspectives from the frontline.Stability of relevant plasma protein activities in cryosupernatant plasma units during refrigerated storage for up to 5 days postthaw.Properties of human asialo-factor VIII. A ristocetin-independent platelet-aggregating agent.Review of antihemophilic factor injection for the routine prophylaxis of bleeding episodes and risk of joint damage in severe hemophilia A.Factor replacement for haemophilia--should cryoprecipitate be used?Platelets have more than one binding site for von Willebrand factor.Antibody to hepatitis B surface antigen in haemophiliacs on long-term therapy with Scottish factor VIII.The history of blood transfusion.Intraoperative cryoprecipitate transfusion and its association with the incidence of biliary complications after liver transplantation--a retrospective cohort studyIsolation, subunit structure, and proteolytic modification of bovine factor VIII.History of pediatric hematology oncology.Management of the haemophilic child.Clinical use of blood, blood components and blood products.Profile of efraloctocog alfa and its potential in the treatment of hemophilia A.Studies on the purification of antihemophilic factor (factor 8. I. Precipitation of antihemophilic factor by concanavalin A.Cryoprecipitate therapy.Diagnosis of haemophilia: use of an artificial factor-VIII-deficient human plasma systemMechanisms of action of immune tolerance induction against factor VIII in patients with congenital haemophilia A and factor VIII inhibitors.A biological standard for measurement of blood coagulation Factor VIII activity.Current options and new developments in the treatment of haemophilia.Factor VIII safety: plasma-derived versus recombinant products.Cryoprecipitate transfusion: assessing appropriateness and dosing in trauma.The modern treatment of haemophilia: a narrative reviewCryoprecipitate: an outmoded treatment?Restoring hemostasis: fibrinogen concentrate versus cryoprecipitate.Changing paradigm of prophylaxis with longer acting factor concentrates.Current Practice in the Treatment of Haemophilia.Small-pool high-yield factor VIII production.The effects of intraoperative cryoprecipitate transfusion on acute renal failure following orthotropic liver transplantation.Bilateral cataract: extraction in classic haemophilia with retrobulbar anaesthesia and peripheral iridectomyA trial of prophylactic replacement therapy in haemophilia and Christmas disease.Haemarthrosis and haemophilia.Biomechanical properties of mixtures of blood and synovial fluidThe glass micropipette electrode: A history of its inventors and users to 1950.Mild hemophilia A as a cause of bleeding in dermatologic surgery.More blood, more life? Reflections on World Blood Donor Day-2011.Cell phones and landlines: the impact of gene therapy on the cost and availability of treatment for hemophilia.Rosemary Biggs MD FRCP (1912-2001) and Katharine Dormandy MD FRCP (1926-78): from laboratory to treatment and care of people with haemophilia.
P2860
Q27027298-4155DB26-5B1C-4E55-9C96-553F68864FB0Q28364459-EEC86937-7B88-44DD-87EC-52D7AD7168C9Q30249256-3896A80C-FA09-4577-8BE9-9A6CF3DC27F4Q33407886-FD57BB66-3074-486B-B0A6-B6CF241BD55EQ33481601-7E1CC93B-8606-4BC8-8763-2B1174770AC9Q33715399-1C57D6AE-B5E4-4E21-A6DF-E2961B9E06A3Q33785729-14D7A333-64A3-4277-B397-E34A345CFFCBQ33821754-38E4B980-400B-46D6-B0A8-DFD1B74F064CQ33846261-4C14BBBB-8F84-4E38-A9E1-75A13FD57542Q33923279-42208C69-87C1-4972-B963-DDBB1EF8C4A9Q34722590-FD71D595-6D6E-4E77-B450-3F21B4A2372BQ34889382-DB26EFED-62D8-4158-BB6A-6BD3E65A78CFQ35001654-7E202804-72CC-4097-8B36-E13A69B2F01CQ35149742-748CC128-EA80-4B97-8FA0-D3898D9E897BQ35227902-A0AAB39A-F3E6-4F56-A890-853DD884EDDCQ35565320-2B17082F-7A4C-4011-864E-02A4D4402AA1Q35567921-A47373F8-4EDB-4FD5-8F57-5B151F6B0893Q36232259-85759EF8-3DC6-44A0-839F-37055A80CCF7Q36526899-0B16D3A4-8913-48C0-978B-E85B2E6AFCBCQ36707550-5A729C62-8069-4B85-92E4-43DBCB2EE992Q36720594-57D6C044-6C96-40CF-B2DB-8BAAD61C1647Q37841547-EBB47CF8-E9B9-4E02-9847-6BC4410AFCBAQ37882787-0662DE86-B451-42C2-AC75-CAD1AFB71D32Q37919554-7B4B58C6-57DE-414C-B7AD-79B802C87934Q38025882-49C35CE1-7A7B-49EA-A65A-19CFB80AEB80Q38044961-B372FC1A-56E6-4E1F-AD2C-0B2A0CF64B17Q38115586-C8DCFA8C-2559-4A37-AB75-25F30F29E6E3Q38206858-749194BC-859E-4665-8ABC-C84802F3B152Q38894036-D5F384CC-00A9-4AF4-A2A9-F3A1AC73CBD9Q39592379-6A4DDA65-FBB1-4327-BC50-ADADFD7F2CB6Q40706922-BA195754-C385-448B-8C23-3A28CA87DFFBQ40856134-0E3657CC-B776-4B7E-92A3-5866765ABA93Q41260785-2B9154E9-4A4E-49CF-AC9D-1D3E10DF382BQ41834832-4CBD0B34-8DCC-4A1E-8A1F-49891BF80799Q41850748-F72BAE21-FDE0-4646-B77B-6678951F781DQ42292876-5D24D390-742C-4574-A45E-F0FACF01AFA1Q42512585-7C180822-4C9E-4753-B2B5-806A12318C0EQ42805084-3E9C5EED-113D-41CE-A38C-60E8C3FA925EQ42933613-540B32B6-251D-4AB3-9D70-D0667375A7E7Q44731239-B75CD2E0-5ADB-4EAC-9773-B1F65F6963C7
P2860
HIGH-POTENCY ANTIHAEMOPHILIC FACTOR CONCENTRATE PREPARED FROM CRYOGLOBULIN PRECIPITATE.
description
1964 nî lūn-bûn
@nan
1964年の論文
@ja
1964年学术文章
@wuu
1964年学术文章
@zh
1964年学术文章
@zh-cn
1964年学术文章
@zh-hans
1964年学术文章
@zh-my
1964年学术文章
@zh-sg
1964年學術文章
@yue
1964年學術文章
@zh-hant
name
HIGH-POTENCY ANTIHAEMOPHILIC FACTOR CONCENTRATE PREPARED FROM CRYOGLOBULIN PRECIPITATE.
@en
HIGH-POTENCY ANTIHAEMOPHILIC FACTOR CONCENTRATE PREPARED FROM CRYOGLOBULIN PRECIPITATE.
@nl
type
label
HIGH-POTENCY ANTIHAEMOPHILIC FACTOR CONCENTRATE PREPARED FROM CRYOGLOBULIN PRECIPITATE.
@en
HIGH-POTENCY ANTIHAEMOPHILIC FACTOR CONCENTRATE PREPARED FROM CRYOGLOBULIN PRECIPITATE.
@nl
prefLabel
HIGH-POTENCY ANTIHAEMOPHILIC FACTOR CONCENTRATE PREPARED FROM CRYOGLOBULIN PRECIPITATE.
@en
HIGH-POTENCY ANTIHAEMOPHILIC FACTOR CONCENTRATE PREPARED FROM CRYOGLOBULIN PRECIPITATE.
@nl
P2093
P356
P1433
P1476
HIGH-POTENCY ANTIHAEMOPHILIC FACTOR CONCENTRATE PREPARED FROM CRYOGLOBULIN PRECIPITATE.
@en
P2093
A R PAPPENHAGEN
E J GERSHGOLD
P2888
P356
10.1038/203312A0
P407
P577
1964-07-01T00:00:00Z
P6179
1037743965